Abstract:
Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.
Abstract:
The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.
Abstract:
The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.
Abstract:
The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions.
Abstract:
This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
Abstract:
The present invention relates to compositions and methods for isolating cells devoid of unwanted viral contaminants, and to methods for preparing a virus stock substantially devoid of viral contaminants. Virus stocks, cells, and immunogenic reagents produced using such methods are also provided.
Abstract:
Methods and compositions are disclosed for modulating the immune system of animals. Applicant has identified that oral administration of immunoglubulin or plasma fractions purified from animal serum can modulate serum IgG and/or TNF-α levels for treatment of autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans.
Abstract:
This invention describes a quick-dissolving thin film strips comprising bioactive components encapsulated within pH-sensitive polymeric microparticles. The microparticles are embedded within the thin film and provide protection to components encapsulated within. The invention further describes methods to incorporate bioactive components encapsulated within pH-sensitive polymeric microparticles into a quick-dissolving thin film strip while maintaining the bioactivity of the contained therapeutic agents during thin film formation and microencapsulation.
Abstract:
Group C rotaviruses are a cause of acute gastroenteritis in children and adults that is distinct from group A RV. However, human group C rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GrpC RV disease. Consequently, the burden of GpC RV disease has not been clearly established. Isolated recombinant human rotavirus group C virus-like particles are provided according to embodiments of the present invention along with methods of their production and use in, inter alia, detection of Grp C RV infection, diagnostic assays and immunogenic compositions.
Abstract translation:C组轮状病毒是与A组RV不同的儿童和成人的急性胃肠炎的原因。 然而,人类C型轮状病毒不能在培养物中生长,导致缺乏用于检测和治疗GrpC RV疾病的工具。 因此,GpC RV疾病的负担尚未明确。 根据本发明的实施方案提供分离的重组人轮状病毒组C病毒样颗粒以及其生产和用于特别是检测Grp C RV感染,诊断测定和免疫原性组合物的方法。
Abstract:
The present invention relates to a vaccine composition comprising a carbohydrate polymer comprising mannose and flu antigen(s) (e.g. whole inactivated influenza virus) in admixture, and a method of immunising a subject comprising the step of administering the vaccine composition to a subject.